Engineered Dendritic Cell Vaccines for Multiple Myeloma

This study tests a personalized vaccine made from a patient's own immune cells (called dendritic cells) that are engineered in the lab to help the immune system fight multiple myeloma — a cancer of the blood plasma cells. **You may be eligible if...** - You have been diagnosed with multiple myeloma or a related tumor called plasmacytoma - Your cancer is in a very good partial remission or complete remission after prior treatment - Your expected survival is more than 12 weeks - You have adequate veins for blood draws or a blood collection procedure (apheresis) - You are willing to give informed consent and attend follow-up visits **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have an active, uncontrolled infection - You have HIV or active hepatitis B or C - You are on ongoing systemic (whole-body) steroid medications (inhaled steroids are okay) Talk to your doctor to see if this trial is right for you.